

## QIBA PET-Amyloid Biomarker Committee

Friday, February 12, 2021 at 9 AM CT

Call Summary

### In attendance:

Dawn Matthews, MS (Co-chair)

Satoshi Minoshima, MD, PhD (Co-chair)

Anne Smith, PhD (Co-chair)

Tammie Benzinger, MD, PhD

Orest Boyko, MD, PhD

Rachid Fahmi, MSc, PhD

Clara Ferreira

Norman Foster, MD

Martin Lodge, PhD

Annelise Malkus, PhD

P. David Mozley, MD

Nancy Obuchowski, PhD

Lindsay Quant, MS, MBA

John Sunderland, PhD

Jean-Luc Vanderheyden, PhD

### RSNA

Joe Koudelik

Julie Lisiecki

**Moderator:** Ms. Matthews

### Publishing the PET Amyloid Profile:

- The BC is collaboratively drafting a paper for peer-reviewed publication to promote QIBA and the Profile
  - Dr. Smith to provide scanner section
  - Dr. Vanderheyden to send section 5.1
  - Ms. Ferreira is finishing section 5.4
- Once all of the sections are incorporated, Ms. Matthews will distribute for BC review
- All to consider what remaining pieces may be integration
- The writing team will try to determine how to relate back to the [FDG manuscript](#)
  - Drs. Sunderland and Wahl may be asked to review and provide feedback
- Collaborators on the paper are as follows:
  - Clara Ferreira (Section 5.4)
  - Norman L. Foster, MD (Section 2)
  - Dawn Matthews, MS
  - Nancy Obuchowski, PhD (Section 4)
  - Anne Smith, PhD (scanner and recon details)
  - Jean-Luc Vanderheyden, PhD (Section 5.1)

### DRO Updates:

- Dr. Fahmi has been testing the DRO with Siemens scanner software to check for linearity
  - Some more investigation of the six DRO versions (based on different noise levels) and the 0.6 GM/WM ratio pons outlier may be needed with Mr. Byrd's assistance
  - The team is down to one or two iterations with the DRO, and Dr. Fahmi shared a graph, with mean vs. noise-free measurements
  - It is important to determine the actual slope value since any deviation from 1.0 would need to be factored into change calculations
  - Noise levels and ratios were changed for the DRO based on recent findings
- Dr. Smith to follow up with Dr. Pierce and Mr. Byrd regarding assistance with the GE software to assist with Ms. Ferreira's testing questions

### Next meeting topics:

- Review the PET Amyloid Profile-related manuscript
- Finalize any DRO questions
- Set the stage for a Tau Profile

### Action items

- Ms. Matthews to follow up with Dr. Pierce and Mr. Byrd; Dr. Smith to follow up with Ms. Ferreira
- Dr. Smith or Ms. Matthews to add a Profile note indicating that data are simulated to ensure that no questions are raised pertaining to HIPAA regulations
- Ms. Matthews to reformat the Profile checklist from Excel to Word for ease of use
- Team to review publication once draft is available

Next call – [March 12<sup>th</sup>](#) at 9 am CT